Clinical
ARC-166 PET agent guides first ARC-706 patient dose
Archeus has started a phase I study pairing the Y-86 ARC-166 diagnostic agent with Y-90 ARC-706 therapy in metastatic cancer patients receiving immune checkpoint inhibitors.
Company
Archeus Technologies